deltatrials
Unknown PHASE2 INTERVENTIONAL 2-arm NCT02489006

A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer (NEO)

A Phase II, Open-Label, Randomized, Multi-Centre Study, of Neoadjuvant Olaparib in Patients With Platinum Sensitive Recurrent High Grade Serous Ovarian/Primary Peritoneal or Fallopian Tube Cancer

Sponsor: University Health Network, Toronto

Conditions Debulking Surgical Procedures Fallopian Tube Cancer Neoadjuvant Treatment Ovarian Cancer
Interventions Olaparib Platinum-based Chemotherapy
Updated 14 times since 2017 Last updated: Jan 14, 2024 Started: Jul 19, 2016 Primary completion: Dec 31, 2025 Completion: Dec 31, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02489006, this PHASE2 trial focuses on Debulking Surgical Procedures and Fallopian Tube Cancer and remains ongoing. Sponsored by University Health Network, Toronto, it has been updated 14 times since 2016, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Aug 2017 · 7 months · monthly snapshot~Aug 2017 – ~Jun 2018 · 10 months · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~Aug 2019 · 9 months · monthly snapshot~Aug 2019 – ~Jan 2020 · 5 months · monthly snapshot~Jan 2020 – ~Jan 2021 · 12 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Jun 2022 · 13 months · monthly snapshot~Jun 2022 – ~Feb 2024 · 20 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Feb 2026 · 5 months · monthly snapshot~Feb 2026 – present · 7 months · monthly snapshot

Change History

14 versions recorded

  1. Feb 2026 — Present [monthly]

    Unknown PHASE2

    Status: Active Not Recruiting → Unknown

  2. Sep 2025 — Feb 2026 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2024 — Sep 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Feb 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 9 earlier versions

  1. Jun 2022 — Feb 2024 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  2. May 2021 — Jun 2022 [monthly]

    Recruiting PHASE2

  3. Jan 2021 — May 2021 [monthly]

    Recruiting PHASE2

  4. Jan 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  5. Aug 2019 — Jan 2020 [monthly]

    Recruiting PHASE2

  6. Nov 2018 — Aug 2019 [monthly]

    Recruiting PHASE2

  7. Jun 2018 — Nov 2018 [monthly]

    Recruiting PHASE2

  8. Aug 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  9. Jan 2017 — Aug 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Jul 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • University Health Network, Toronto
Data source: University Health Network, Toronto

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations